Mink's novel fap-car-inkt presented at asgct

New york, may 18, 2023 (globe newswire) -- mink therapeutics (nasdaq: inkt), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today presented preclinical data demonstrating the potential of its novel fap-car-inkt candidate, mink-215, at the american society of gene and cell therapy (asgct) annual meeting.
INKT Ratings Summary
INKT Quant Ranking